{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:27:43Z","timestamp":1786519663751,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["12ZB921N"],"award-info":[{"award-number":["12ZB921N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1S03023N"],"award-info":[{"award-number":["1S03023N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1SHDF24N"],"award-info":[{"award-number":["1SHDF24N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1SF7124N"],"award-info":[{"award-number":["1SF7124N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1SA1V26N"],"award-info":[{"award-number":["1SA1V26N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011878","name":"Flemish government","doi-asserted-by":"crossref","award":["VR 2025 1212 DOC.1188\/2"],"award-info":[{"award-number":["VR 2025 1212 DOC.1188\/2"]}],"id":[{"id":"10.13039\/501100011878","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Current antiretroviral therapies suppress HIV replication but fail to eliminate integrated proviral DNA in long-lived CD4\u207a cells, precluding a cure. CRISPR-Cas9 offers potential for HIV eradication but efficient and cell-specific delivery into HIV target cells remains a major hurdle. We developed CD4-directed Nanoblades (CD4-NBs), murine leukemia virus-like particles pseudotyped with anti-CD4 nanobodies and a fusogenic glycoprotein VSV Gmut, to selectively deliver Cas9-gRNA ribonucleoproteins into CD4\u207a cells. CD4-NBs selectively delivered cargo to CD4\u207a cells in vitro and in vivo, achieving efficient gene disruption in primary CD4\n                    <jats:sup>+<\/jats:sup>\n                    cells. Dual-guide CD4-NBs targeting conserved HIV\n                    <jats:italic>tat<\/jats:italic>\n                    \/\n                    <jats:italic>rev<\/jats:italic>\n                    \/\n                    <jats:italic>env<\/jats:italic>\n                    regions disrupted proviral DNA, suppressing HIV infection in CD4\n                    <jats:sup>+<\/jats:sup>\n                    cells. In HIV-infected, ART-pretreated humanized mice, CD4-NBs significantly reduced plasma viremia. While full tissue reservoir clearance was not achieved, repeated dosing did reduce viral RNA and proviral DNA in bone marrow and lungs, respectively. As such, this proof-of-concept study supports the promise of CD4-NBs as a minimally invasive, CD4\u207a cell-targeted gene editing strategy for HIV therapy.\n                  <\/jats:p>","DOI":"10.1038\/s44321-026-00481-x","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:21:41Z","timestamp":1783354901000},"page":"3345-3373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD4-directed nanoblades enable selective genome editing in CD4+ cells and HIV suppression in vitro and in vivo"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1598-3057","authenticated-orcid":false,"given":"Jolien","family":"Van Cleemput","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6157-3684","authenticated-orcid":false,"given":"Maaike","family":"De Cock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rianne","family":"Verbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elianne","family":"Burg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram","family":"Van den Eeckhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Witkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"van Snippenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Stylianidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Brugger Galetic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareva","family":"Delporte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Bracke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gerlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8600-1631","authenticated-orcid":false,"given":"Linos","family":"Vandekerckhove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"481_CR1","doi-asserted-by":"publisher","first-page":"101881","DOI":"10.1016\/j.isci.2020.101881","volume":"24","author":"P Adams","year":"2021","unstructured":"Adams P, Fievez V, Schober R, Amand M, Iserentant G, Rutsaert S, Dessilly G, Vanham G, Hedin F, Cosma A et al (2021) CD32+CD4+ memory T cells are enriched for total HIV-1 DNA in tissues from humanized mice. iScience 24:101881","journal-title":"iScience"},{"key":"481_CR2","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","volume":"185","author":"S Banskota","year":"2022","unstructured":"Banskota S, Raguram A, Suh S, Du SW, Davis JR, Choi EH, Wang X, Nielsen SC, Newby GA, Randolph PB et al (2022) Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell 185:250\u2013265.e16","journal-title":"Cell"},{"key":"481_CR3","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.3390\/vaccines10111946","volume":"10","author":"R Bezbaruah","year":"2022","unstructured":"Bezbaruah R, Chavda VP, Nongrang L, Alom S, Deka K, Kalita T, Ali F, Bhattacharjee B, Vora L (2022) Nanoparticle-based delivery systems for vaccines. Vaccines 10:1946","journal-title":"Vaccines"},{"key":"481_CR4","first-page":"3076","volume":"117","author":"E Billerbeck","year":"2011","unstructured":"Billerbeck E, Barry WT, Mu K, Dorner M, Rice CM, Ploss A (2011) Development of human CD4+ Foxp3+ regulatory T cells in human stem cell factor\u2013, granulocyte-macrophage colony-stimulating factor\u2013, and interleukin-3\u2013expressing NOD-SCID IL2R\u03b3null humanized mice. Blood J Am Soc Hematol 117:3076\u20133086","journal-title":"Blood J Am Soc Hematol"},{"key":"481_CR5","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/jbm.a.36315","volume":"106","author":"S Cao","year":"2018","unstructured":"Cao S, Jiang Y, Levy CN, Hughes SM, Zhang H, Hladik F, Woodrow KA (2018) Optimization and comparison of CD4-targeting lipid\u2013polymer hybrid nanoparticles using different binding ligands. J Biomed Mater Res A 106:1177\u20131188","journal-title":"J Biomed Mater Res A"},{"key":"481_CR6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(25)01186-9","volume":"406","author":"DM Cavalcanti","year":"2025","unstructured":"Cavalcanti DM, de Oliveira Ferreira de Sales L, da Silva AF, Basterra EL, Pena D, Monti C, Barreix G, Silva NJ, Vaz P, Saute F et al (2025) Evaluating the impact of two decades of USAID interventions and projecting the effects of defunding on mortality up to 2030: a retrospective impact evaluation and forecasting analysis. Lancet 406:283\u2013294","journal-title":"Lancet"},{"key":"481_CR7","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1021\/acsnano.0c09514","volume":"15","author":"PM Cevaal","year":"2021","unstructured":"Cevaal PM, Ali A, Czuba-Wojnilowicz E, Symons J, Lewin SR, Cortez-Jugo C, Caruso F (2021) In Vivo T cell-targeting nanoparticle drug delivery systems: considerations for rational design. ACS Nano 15:3736\u20133753","journal-title":"ACS Nano"},{"key":"481_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/MRA.00179-20","volume":"9","author":"C-H Chung","year":"2020","unstructured":"Chung C-H, Mele AR, Allen AG, Costello R, Dampier W, Nonnemacher MR, Wigdahl B (2020) Integrated human immunodeficiency virus type 1 sequence in J-Lat 10.6. Microbiol Resour Announc 9:10\u20131128","journal-title":"Microbiol Resour Announc"},{"key":"481_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/bmb\/58.1.43","volume":"58","author":"PR Clapham","year":"2001","unstructured":"Clapham PR, McKnight \u00c1 (2001) HIV-1 receptors and cell tropism. Br Med Bull 58:43\u201359","journal-title":"Br Med Bull"},{"key":"481_CR10","first-page":"81","volume":"38","author":"AT Das","year":"2019","unstructured":"Das AT, Binda CS, Berkhout B (2019) Elimination of infectious HIV DNA by CRISPR\u2013Cas9. Eng Viral Resist 38:81\u201388","journal-title":"Eng Viral Resist"},{"key":"481_CR11","doi-asserted-by":"publisher","first-page":"e2217887120","DOI":"10.1073\/pnas.2217887120","volume":"120","author":"PK Dash","year":"2023","unstructured":"Dash PK, Chen C, Kaminski R, Su H, Mancuso P, Sillman B, Zhang C, Liao S, Sravanam S, Liu H (2023) CRISPR editing of CCR5 and HIV-1 facilitates viral elimination in antiretroviral drug-suppressed virus-infected humanized mice. Proc Natl Acad Sci USA 120:e2217887120","journal-title":"Proc Natl Acad Sci USA"},{"key":"481_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10366-y","volume":"10","author":"PK Dash","year":"2019","unstructured":"Dash PK, Kaminski R, Bella R, Su H, Mathews S, Ahooyi TM, Chen C, Mancuso P, Sariyer R, Ferrante P et al (2019) Sequential LASER ART and CRISPR treatments eliminate HIV-1 in a subset of infected humanized mice. Nat Commun 10:2753","journal-title":"Nat Commun"},{"key":"481_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/clinchem\/hvae192","volume":"71","author":"M Delporte","year":"2025","unstructured":"Delporte M, Lambrechts L, Blomme EE, van Snippenberg W, Rutsaert S, Verschoore M, De Smet E, Noppe Y, De Langhe N, De Scheerder M-A et al (2025) Integrative assessment of total and intact HIV-1 reservoir by a 5-region multiplexed rainbow DNA digital PCR assay. Clin Chem 71:203\u2013214","journal-title":"Clin Chem"},{"key":"481_CR14","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1016\/j.ymthe.2024.08.002","volume":"32","author":"MB Demircan","year":"2024","unstructured":"Demircan MB, Zinser LJ, Michels A, Guaza-Lasheras M, John F, Gorol JM, Theuerkauf SA, G\u00fcnther DM, Grimm D, Greten FR et al (2024) T-cell specific in vivo gene delivery with DART-AAVs targeted to CD8. Mol Ther 32:3470\u20133484","journal-title":"Mol Ther"},{"key":"481_CR15","unstructured":"Foss DV, Srishti S, Manohar B, Wilson RC (2022) Peptide-enabled CRISPR enzyme delivery for versatile ex vivo T cell engineering and in vivo editing of the brain. Genome Eng CRISPR Front:55"},{"key":"481_CR16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.nantod.2015.06.006","volume":"10","author":"HH Gustafson","year":"2015","unstructured":"Gustafson HH, Holt-Casper D, Grainger DW, Ghandehari H (2015) Nanoparticle uptake: the phagocyte problem. Nano Today 10:487\u2013510","journal-title":"Nano Today"},{"key":"481_CR17","doi-asserted-by":"publisher","first-page":"e0261269","DOI":"10.1371\/journal.pone.0261269","volume":"16","author":"MV Hamann","year":"2021","unstructured":"Hamann MV, Beschorner N, Vu X-K, Hauber I, Lange UC, Traenkle B, Kaiser PD, Foth D, Schneider C, B\u00fcning H et al (2021) Improved targeting of human CD4+ T cells by nanobody-modified AAV2 gene therapy vectors. PLoS ONE 16:e0261269","journal-title":"PLoS ONE"},{"key":"481_CR18","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/s41587-023-02085-z","volume":"42","author":"JR Hamilton","year":"2024","unstructured":"Hamilton JR, Chen E, Perez BS, Sandoval Espinoza CR, Kang MH, Trinidad M, Ngo W, Doudna JA (2024) In vivo human T cell engineering with enveloped delivery vehicles. Nat Biotechnol 42:1684\u20131692","journal-title":"Nat Biotechnol"},{"key":"481_CR19","doi-asserted-by":"publisher","first-page":"109207","DOI":"10.1016\/j.celrep.2021.109207","volume":"35","author":"JR Hamilton","year":"2021","unstructured":"Hamilton JR, Tsuchida CA, Nguyen DN, Shy BR, McGarrigle ER, Sandoval Espinoza CR, Carr D, Blaeschke F, Marson A, Doudna JA (2021) Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering. Cell Rep 35:109207","journal-title":"Cell Rep"},{"key":"481_CR20","doi-asserted-by":"publisher","first-page":"103678","DOI":"10.1016\/j.ebiom.2021.103678","volume":"73","author":"J Herskovitz","year":"2021","unstructured":"Herskovitz J, Hasan M, Patel M, Blomberg WR, Cohen JD, Machhi J, Shahjin F, Mosley RL, McMillan J, Kevadiya BD et al (2021) CRISPR-Cas9 mediated exonic disruption for HIV-1 elimination. eBioMedicine 73:103678","journal-title":"eBioMedicine"},{"key":"481_CR21","doi-asserted-by":"publisher","first-page":"681062","DOI":"10.3389\/fimmu.2021.681062","volume":"12","author":"DA Horwitz","year":"2021","unstructured":"Horwitz DA, Bickerton S, La Cava A (2021) Strategies to use nanoparticles to generate CD4 and CD8 regulatory T cells for the treatment of SLE and other autoimmune diseases. Front Immunol 12:681062","journal-title":"Front Immunol"},{"key":"481_CR22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.omtm.2019.03.003","volume":"13","author":"A Jamali","year":"2019","unstructured":"Jamali A, Kapitza L, Schaser T, Johnston ICD, Buchholz CJ, Hartmann J (2019) Highly efficient and selective CAR-gene transfer using CD4- and CD8-targeted lentiviral vectors. Mol Ther Methods Clin Dev 13:371\u2013379","journal-title":"Mol Ther Methods Clin Dev"},{"key":"481_CR23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41586-020-2651-8","volume":"585","author":"C Jiang","year":"2020","unstructured":"Jiang C, Lian X, Gao C, Sun X, Einkauf KB, Chevalier JM, Chen SMY, Hua S, Rhee B, Chang K et al (2020) Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature 585:261\u2013267","journal-title":"Nature"},{"key":"481_CR24","doi-asserted-by":"crossref","unstructured":"Kneissl S, Abel T, Rasbach A, Brynza J, Schneider-Schaulies J, Buchholz CJ (2012) Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies. PLoS ONE 7:e46667","DOI":"10.1371\/journal.pone.0046667"},{"key":"481_CR25","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1056\/NEJMoa1110187","volume":"368","author":"T Le","year":"2013","unstructured":"Le T, Wright EJ, Smith DM, He W, Catano G, Okulicz JF, Young JA, Clark RA, Richman DD, Little SJ (2013) Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med 368:218\u2013230","journal-title":"N Engl J Med"},{"key":"481_CR26","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1073\/pnas.0306764101","volume":"101","author":"DN Levy","year":"2004","unstructured":"Levy DN, Aldrovandi GM, Kutsch O, Shaw GM (2004) Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci USA 101:4204\u20134209","journal-title":"Proc Natl Acad Sci USA"},{"key":"481_CR27","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.3390\/v13122461","volume":"13","author":"Y Liu","year":"2021","unstructured":"Liu Y, Jeeninga RE, Klaver B, Berkhout B, Das AT (2021) Transient CRISPR-Cas treatment can prevent reactivation of HIV-1 replication in a latently infected T-cell line. Viruses 13:2461","journal-title":"Viruses"},{"key":"481_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07845-z","volume":"10","author":"PE Mangeot","year":"2019","unstructured":"Mangeot PE, Risson V, Fusil F, Marnef A, Laurent E, Blin J, Mournetas V, Massourid\u00e8s E, Sohier TJM, Corbin A et al (2019) Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins. Nat Commun 10:45","journal-title":"Nat Commun"},{"key":"481_CR29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.virol.2018.05.016","volume":"520","author":"AL Mefferd","year":"2018","unstructured":"Mefferd AL, Bogerd HP, Irwan ID, Cullen BR (2018) Insights into the mechanisms underlying the inactivation of HIV-1 proviruses by CRISPR\/Cas. Virology 520:116\u2013126","journal-title":"Virology"},{"key":"481_CR30","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/jlb.52.1.128","volume":"52","author":"SC Moore","year":"1992","unstructured":"Moore SC, Anderson SJ, Walker WS (1992) Mouse macrophages contain a truncated CD4 transcript. J Leukoc Biol 52:128\u2013129","journal-title":"J Leukoc Biol"},{"key":"481_CR31","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","volume":"82","author":"S Muyldermans","year":"2013","unstructured":"Muyldermans S (2013) Nanobodies: natural single-domain antibodies. Annu Rev Biochem 82:775\u2013797","journal-title":"Annu Rev Biochem"},{"key":"481_CR32","doi-asserted-by":"publisher","first-page":"100018","DOI":"10.1016\/j.ggedit.2022.100018","volume":"3\u20134","author":"K Nakamae","year":"2022","unstructured":"Nakamae K, Bono H (2022) Genome editing and bioinformatics. Gene Genome Ed 3\u20134:100018","journal-title":"Gene Genome Ed"},{"key":"481_CR33","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3390\/v12111223","volume":"12","author":"Y Ophinni","year":"2020","unstructured":"Ophinni Y, Miki S, Hayashi Y, Kameoka M (2020) Multiplexed tat-Targeting CRISPR-Cas9 protects T cells from acute HIV-1 infection with inhibition of viral escape. Viruses 12:1223","journal-title":"Viruses"},{"key":"481_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44020-5","volume":"14","author":"M Pardons","year":"2023","unstructured":"Pardons M, Cole B, Lambrechts L, van Snippenberg W, Rutsaert S, Noppe Y, De Langhe N, Dhondt A, Vega J, Eyassu F et al (2023) Potent latency reversal by Tat RNA-containing nanoparticle enables multi-omic analysis of the HIV-1 reservoir. Nat Commun 14:8397","journal-title":"Nat Commun"},{"key":"481_CR35","doi-asserted-by":"publisher","first-page":"6706","DOI":"10.1021\/acsnano.5b02796","volume":"9","author":"S Ramishetti","year":"2015","unstructured":"Ramishetti S, Kedmi R, Goldsmith M, Leonard F, Sprague AG, Godin B, Gozin M, Cullis PR, Dykxhoorn DM, Peer D (2015) Systemic gene silencing in primary T lymphocytes using targeted lipid nanoparticles. ACS Nano 9:6706\u20136716","journal-title":"ACS Nano"},{"key":"481_CR36","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed LJ, M\u00fcench H (1938) A simple method of estimating fifty per cent endpoints. Am J Epidemiol 27:493\u2013497","journal-title":"Am J Epidemiol"},{"key":"481_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/btm2.10049","volume":"2","author":"MJ Rohovie","year":"2017","unstructured":"Rohovie MJ, Nagasawa M, Swartz JR (2017) Virus-like particles: Next-generation nanoparticles for targeted therapeutic delivery. Bioeng Transl Med 2:43\u201357","journal-title":"Bioeng Transl Med"},{"key":"481_CR38","unstructured":"Roobrouck A, Stortelers C, Conde M, Staelens S, Soares H, Schols D, Vanlandschoot P (2015) Bispecific nanobodies. Patent nr. WO\/2015\/044386. https:\/\/patents.google.com\/patent\/WO2015044386A1\/en"},{"key":"481_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01830-8","volume":"8","author":"D Schmid","year":"2017","unstructured":"Schmid D, Park CG, Hartl CA, Subedi N, Cartwright AN, Puerto RB, Zheng Y, Maiarana J, Freeman GJ, Wucherpfennig KW et al (2017) T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. Nat Commun 8:1747","journal-title":"Nat Commun"},{"key":"481_CR40","doi-asserted-by":"publisher","first-page":"101268","DOI":"10.1016\/j.xcrm.2023.101268","volume":"4","author":"A Sponaugle","year":"2023","unstructured":"Sponaugle A, Weideman AMK, Ranek J, Atassi G, Kuruc J, Adimora AA, Archin NM, Gay C, Kuritzkes DR, Margolis DM et al (2023) Dominant CD4+ T cell receptors remain stable throughout antiretroviral therapy-mediated immune restoration in people with HIV. Cell Rep Med 4:101268","journal-title":"Cell Rep Med"},{"key":"481_CR41","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1056\/NEJMoa1300662","volume":"370","author":"P Tebas","year":"2014","unstructured":"Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, Spratt SK, Surosky RT, Giedlin MA, Nichol G (2014) Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 370:901\u2013910","journal-title":"N Engl J Med"},{"key":"481_CR42","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1016\/j.ymthe.2021.06.004","volume":"29","author":"I Tomb\u00e1cz","year":"2021","unstructured":"Tomb\u00e1cz I, Laczk\u00f3 D, Shahnawaz H, Muramatsu H, Natesan A, Yadegari A, Papp TE, Alameh M-G, Shuvaev V, Mui BL et al (2021a) Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs. Mol Ther 29:3293\u20133304","journal-title":"Mol Ther"},{"key":"481_CR43","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1016\/j.ymthe.2021.06.004","volume":"29","author":"I Tomb\u00e1cz","year":"2021","unstructured":"Tomb\u00e1cz I, Laczk\u00f3 D, Shahnawaz H, Muramatsu H, Natesan A, Yadegari A, Papp TE, Alameh M-G, Shuvaev V, Mui BL et al (2021b) Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs. Mol Ther 29:3293\u20133304","journal-title":"Mol Ther"},{"key":"481_CR44","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cell.2020.03.023","volume":"181","author":"D Wang","year":"2020","unstructured":"Wang D, Zhang F, Gao G (2020) CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. Cell 181:136\u2013150","journal-title":"Cell"},{"key":"481_CR45","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","volume":"406","author":"J Xu","year":"2025","unstructured":"Xu J, Liu L, Parone P, Xie W, Sun C, Chen Z, Zhang J, Li C, Hu Y, Mei H (2025) In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma. Lancet 406:228\u2013231","journal-title":"Lancet"},{"key":"481_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/srep29530","volume":"6","author":"KE Yoder","year":"2016","unstructured":"Yoder KE, Bundschuh R (2016) Host double strand break repair generates HIV-1 strains resistant to CRISPR\/Cas9. Sci Rep 6:29530","journal-title":"Sci Rep"},{"key":"481_CR47","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.1016\/j.cell.2022.11.016","volume":"185","author":"B Yu","year":"2022","unstructured":"Yu B, Shi Q, Belk JA, Yost KE, Parker KR, Li R, Liu BB, Huang H, Lingwood D, Greenleaf WJ et al (2022) Engineered cell entry links receptor biology with single-cell genomics. Cell 185:4904\u20134920.e22","journal-title":"Cell"},{"key":"481_CR48","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.4049\/jimmunol.1500956","volume":"195","author":"Q Zhou","year":"2015","unstructured":"Zhou Q, Uhlig KM, Muth A, Kimpel J, L\u00e9vy C, M\u00fcnch RC, Seifried J, Pfeiffer A, Trkola A, Coulibaly C et al (2015) Exclusive transduction of human CD4+ T cells upon systemic delivery of CD4-targeted lentiviral vectors. J Immunol 195:2493","journal-title":"J Immunol"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00481-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-026-00481-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00481-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:31:56Z","timestamp":1786516316000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-026-00481-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,12]]}},"alternative-id":["481"],"URL":"https:\/\/doi.org\/10.1038\/s44321-026-00481-x","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}